When treating patients with low risk HR + BC (defined by HER2 negative, less than 1 cm tumors and negative lymph nodes), 65% of physicians recommend only ET, 26.9% recommend ET and chemotherapy,7.1% only chemotherapy and <1% ET and Oncotype assessment (Figure 2). This evidence concerns the gene ERBB2 and breast cancer.